The Chemours Company $CC Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lessened its holdings in The Chemours Company (NYSE:CC) by 55.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 60,718 shares of the specialty chemicals company’s stock after selling 75,750 shares during the quarter. Intech Investment Management LLC’s holdings in Chemours were worth $695,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Yousif Capital Management LLC raised its stake in Chemours by 1.6% during the 2nd quarter. Yousif Capital Management LLC now owns 62,386 shares of the specialty chemicals company’s stock worth $714,000 after acquiring an additional 968 shares in the last quarter. CWM LLC lifted its position in Chemours by 34.7% during the 2nd quarter. CWM LLC now owns 4,290 shares of the specialty chemicals company’s stock worth $49,000 after acquiring an additional 1,104 shares during the period. Inspire Investing LLC grew its position in Chemours by 5.7% in the 1st quarter. Inspire Investing LLC now owns 25,156 shares of the specialty chemicals company’s stock valued at $340,000 after buying an additional 1,357 shares during the last quarter. State of Wyoming boosted its holdings in shares of Chemours by 13.4% in the first quarter. State of Wyoming now owns 13,978 shares of the specialty chemicals company’s stock valued at $189,000 after acquiring an additional 1,657 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in Chemours by 130.7% during the 2nd quarter. GAMMA Investing LLC now owns 3,175 shares of the specialty chemicals company’s stock worth $36,000 after purchasing an additional 1,799 shares during the period. Institutional investors and hedge funds own 76.26% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on CC shares. UBS Group cut their price target on shares of Chemours from $21.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, November 11th. Royal Bank Of Canada reduced their price objective on Chemours from $19.00 to $17.00 and set an “outperform” rating on the stock in a research report on Monday, November 10th. Mizuho cut their price target on Chemours from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, October 16th. Zacks Research lowered shares of Chemours from a “hold” rating to a “strong sell” rating in a report on Friday, October 17th. Finally, Truist Financial reduced their target price on Chemours from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $17.50.

Chemours Price Performance

Shares of NYSE CC opened at $12.49 on Thursday. The company has a quick ratio of 0.88, a current ratio of 1.71 and a debt-to-equity ratio of 13.66. The business has a 50 day moving average price of $13.73 and a two-hundred day moving average price of $13.21. The firm has a market cap of $1.87 billion, a PE ratio of -5.62 and a beta of 1.64. The Chemours Company has a fifty-two week low of $9.13 and a fifty-two week high of $22.38.

Chemours (NYSE:CC) last posted its quarterly earnings data on Thursday, November 6th. The specialty chemicals company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.04). The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.50 billion. Chemours had a negative net margin of 5.70% and a positive return on equity of 35.27%. The company’s revenue was down .9% compared to the same quarter last year. During the same quarter last year, the company earned $0.40 earnings per share. Chemours has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts expect that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Friday, November 14th will be issued a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Friday, November 14th. Chemours’s payout ratio is currently -15.77%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.